SCHEMBL5315364

SCHEMBL5315364

N#Cc1ccc(CNC(=O)CCl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
LOXL2 Q9Y4K0 1/20 0.52
MCL1 Q07820 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
CNR1 P21554 1/20 0.47
SAE1 Q9UBE0 1/20 0.46
UBA2 Q9UBT2 1/20 0.46
CYP19A1 P11511 1/20 0.46
AKR1B1 P15121 1/20 0.45
ERCC1 P07992 1/20 0.45
ERCC4 Q92889 1/20 0.45
TPSAB1 Q15661 2/20 0.44
MAPK1 P28482 1/20 0.44
ALDH1A1 P00352 3/20 0.44
HTT P42858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17372408 0.87 CA12 (0.50) EPHX2CA12CA1CA2CA7
SCHEMBL7934897 0.83 EPHX2 (0.52) EPHX2CA12CA1CA2CA7
SCHEMBL15630672 0.83 EPHX2 (0.52) EPHX2CA12CA1CA2CA7
SCHEMBL19049390 0.83 LOXL2 (0.56) EPHX2CA12CA1CA2CA7
SCHEMBL8130378 0.82 MEN1 (0.50) EPHX2CA12CA1CA2CA7
SCHEMBL7879611 0.81 MEN1 (0.66) CA12CA1CA2MEN1KMT2A
SCHEMBL1695664 0.80 LOXL2 (0.57) EPHX2CA12CA1CA2CA7
SCHEMBL6444359 0.80 LOXL2 (0.57) EPHX2CA12CA1CA2CA7
SCHEMBL19002484 0.80 CYP3A4 (0.56) EPHX2CA12CA1CA2CA7
SCHEMBL9798143 0.80 ALDH1A1 (0.58) EPHX2MEN1KMT2ATPSAB1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592356-B2 Triazoles as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2009-09-22 US disclosed
US-7592356-B2 Triazoles as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2009-09-22 US disclosed
US-7511061-B2 Triazoles as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-31 US disclosed
US-7511061-B2 Triazoles as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-31 US disclosed
US-20080103150-A1 Triazoles as Farnesyl Transferase Inhibitors SAHA ASHIS K 2008-05-01 US disclosed
US-20080103150-A1 Triazoles as Farnesyl Transferase Inhibitors SAHA ASHIS K 2008-05-01 US disclosed
WO-2007069986-A1 NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103150-A1 Triazoles as Farnesyl Transferase Inhibitors CYP7A1, HSD3B1, CES1 EPHX2 352/4885CA12 4459/4885CA1 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.